PF-03049423 free base
Modify Date: 2024-01-21 16:28:12
PF-03049423 free base structure
|
Common Name | PF-03049423 free base | ||
|---|---|---|---|---|
| CAS Number | 954138-07-9 | Molecular Weight | 468.54900 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H32N6O4 | Melting Point | N/A | |
| MSDS | Chinese | Flash Point | N/A | |
Use of PF-03049423 free basePF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke[1]. |
| Name | 3-[4-(2-Hydroxyethyl)-1-piperazinyl]-7-(6-methoxy-3-pyridinyl)-1- (2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one |
|---|
| Description | PF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke[1]. |
|---|---|
| Related Catalog | |
| Target |
PDE5A rat and human platelet enzyme:~0.2 nM (IC50) |
| In Vivo | PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion[1]. PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory–motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion[1]. Animal Model: Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) model[1] Dosage: 0.1, 1, or 10 mg/kg Administration: Subcutaneous injection, b.i.d. for 7 days Result: Improved functional recovery at 1 mg/kg and 10 mg/kg. |
| Molecular Formula | C24H32N6O4 |
|---|---|
| Molecular Weight | 468.54900 |
| Exact Mass | 468.24900 |
| PSA | 105.84000 |
| LogP | 1.40590 |